
Mary Walsh
Articles
-
1 month ago |
healio.com | Regina Schaffer |Richard Smith |Mary Walsh |Amish N. Raval
Key takeaways: Select adults with ischemic heart failure with reduced ejection fraction may derive benefit from an investigational cell therapy. A new trial will commence for patients with HFrEF and elevated NT-proBNP. CHICAGO — An autologous point-of-care cell therapy for adults with ischemic HF with reduced ejection fraction was safe and may be beneficial for select candidates, though a pivotal study did not meet its primary efficacy outcome.
-
2 months ago |
healio.com | Erik Swain |Katie Kalvaitis |Mary Walsh
Tirzepatide improves outcomes in HFpEF, obesity regardless of kidney function• The clinical benefits of tirzepatide in patients with HFpEF and obesity were consistent regardless of kidney function. • The effect of tirzepatide on kidney function depends on how CKD is defined, researchers said.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →